ISRCTN60687844已完成未知
A pilot, randomised placebo-controlled study of cognitive enhancer and cognitive training combination: testing a therapeutic paradigm for cognitive impairment in schizophrenia
King's College London (KCL) (UK)0 个研究点目标入组 49 人开始时间: 2010年10月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 49
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) diagnosis of schizophrenia or schizoaffective disorder confirmed by Mini International Neuropsychiatric Interview (MINI)
- •2. Age between 18 and 50 years
- •3. Males and females
- •4. Duration of illness equal to or greater than one year
- •5. Patients should be clinically stable in a non-acute phase for at least 8 weeks prior to the screening visit
- •6. Subjects will meet the following symptom criteria
- •6.1. Positive and Negative Syndrome Scale (PANSS) Conceptual Disorganization item score less than or equal to 4
- •6.2. PANSS Hallucinatory Behaviour or Unusual Thought Content item scores less than or equal to 4
- •6.3. PANSS Negative Subscale scores on all items less than or equal to 4
- •7. Subjects will meet the following cognitive performance criteria
- •7.1. Raw score of 6 or greater on the Wechsler Test of Adult Reading (WTAR)
- •8. Treatment with stable doses of atypical antipsychotics for at least 4 weeks prior to the screening visit
- •9. Negative result in the urine pregnancy test performed during the screening visit in women of childbearing potential (not surgically sterile or 2 years postmenopausal)
- •10.Women of child-bearing potential, who are sexually active, will be considered as potential participants if they are using acceptable methods of contraception, which include barrier method with spermicide, intrauterine device (IUD), steroidal contraceptive (oral, transdermal, implanted, and injected). Women on combined and progestogen-only contraceptives and on contraceptive patches and vaginal rings will be required to use additional contraceptive precautions for the duration of the trial and 4 weeks after stopping taking modafinil for the study purposes because modafinil may reduce the effectiveness of both combined and progestogen-only contraceptives.
- •11. Subjects must read and write in English at a level sufficient to understand and complete study-related procedures
- •12. Written and witnessed informed consent
排除标准
- •1. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) diagnosis of alcohol or substance abuse (other than nicotine) within the last month or a DSM-IV diagnosis of alcohol or substance dependence (other than nicotine) in the last 6 months preceding the screening visit
- •2. Treatment with clozapine
- •3. Treatment with modafinil
- •4. Current treatment (within 4 weeks) with psychotropic agents known to affect cognition: amphetamines, barbiturates, lithium, Monoamine Oxidase Inhibitors (MAOIs), methylphenidate, benzodiazepines, anticholinergics
- •5. Current treatment (within 4 weeks) with cyclosporine (modafinil reduces plasma concentration of cyclosporine), phenytoin (modafinil possibly increases plasma concentration of phenytoin), anticoagulants (modafinil increases the levels of anticoagulants), tricyclic antidepressants (modafinil may increase their levels)
- •6. Pregnant or breast-feeding women
- •7. Clinically significant abnormalities on physical examination
- •8. History of a serious neurological disorder or a systemic illness with known neurological complications
- •9. Hypertension, arrhythmia, left ventricular hypertrophy, cor pulmonale, or clinically significant signs of central nervous system (CNS) stimulant-induced mitral valve prolapse (including ischaemic electrocardiogram [ECG] changes, chest pain and arrhythmias), which pose a risk to the patient if they were to participate in the study
- •10. Any known drug allergies, including sensitivity to modafinil, and the development of drug-associated rash in the past
- •11. Unwillingness or inability to follow or comply with the procedures outlined in the protocol
- •12. Prior participation in a clinical trial of any psychotropic medication in the last 2 months preceding the screening visit
研究者
相似试验
已完成
不适用
Effect of coenzyme Q10 in fibromyalgia patients: study of symptoms and gene expressioFibromyalgiaISRCTN21164124Andalusian Federation of Fibromyalgia and Chronic Fatigue Syndrome (Spain)20
已完成
不适用
A pilot randomized placebo controlled study of the Neutrophil Elastase Inhibitor, Sivelestat, in Patients Undergoing Cardiac Surgerycoronary artery bypass patientsJPRN-UMIN000001687agoya University Hospital Department of Cardiac Surgery20
已完成
2 期
The safety and efficacy of a locally available probiotic in premature infants.ACTRN12609000374268Womens and Childrens Health Service120
已完成
不适用
A study of the preventive effects of an Echinacea extract upon the occurrence of respiratory infections in healthy studentspper respiratory tract infectionsRespiratoryUpper respiratory tract infectionsISRCTN16713057niversity of Wolverhampton60
已完成
不适用
Pilot study of a randomised controlled trial of antenatal thromboprophylaxisPregnancy and childbirth: thromboembolic disease (TED)Pregnancy and ChildbirthThromboembolic disease (TED)ISRCTN21644138HS R&D Regional Programme Register - Department of Health (UK)16